Transplantation · 2003 · 29 citations · 32 references
Life SciencesImmunologyMolecular BiologyGene DeliveryGene TherapyTransplant ImmunologyGraft SurvivalIn Vivo Gene DeliverySystemic Gene DeliveryTransplant ImmunotherapyAdenoviral VectorsAdenovirus BiologyAdenovirus VectorsComposite Tissue GraftingComposite Tissue TransferCytotoxic T Lymphocyte Antigen 4Cytotoxic T-lymphocyte Antigen 4 (Ctla-4) PathwayTransplantation
BACKGROUND: The blockade of costimulatory signal pathway by anti-CD40 ligand antibody or cytotoxic T lymphocyte antigen 4 immunoglobulin (CTLA4Ig) prolongs allograft survival in various vascularized organ transplantations. Because of the short half life of these agents, repeated administration of proteins is required to achieve significant graft survival. Furthermore, there is limited information regarding the effect of cosimulatory blockade on the survival of composite tissue allografts. Therefore, we examined the effect of adenovirus-mediated gene transfer of CTLA4Ig or CD40Ig gene or both in composite tissue allotransplantation. METHODS: The hind limbs removed from male ACI rats (RT1 ) were transplanted into female Lewis rats (RT1 ) heterotopically. The recombinant adenovirus carrying CTLA4Ig (AxCTLA4Ig) or CD40Ig (AxCD40Ig) was intravenously administered after limb transplantation. RESULTS: Limb allograft survival was significantly prolonged by either AxCTLA4Ig or AxCD40Ig treatment at 1 x 10 plaque forming unit (mean survival time [MST] of 39.4+/-6.0 and 13.0+/-2.9, respectively) compared with the adenovirus vector containing beta-galactosidase-treated group (MST of 4.8+/-0.8). Combination of AxCTLA4Ig and AxCD40Ig led to significant prolongation of graft survival (MST of 49.2+/-6.6). Serum levels of CD40Ig were higher in rats treated with combination therapy than those treated with AxCD40Ig alone, whereas the serum levels of CTLA4Ig in rats treated with AxCTLA4Ig alone and AxCTLA4Ig and AxCD40Ig combined were very similar. CONCLUSION: This study indicates that an adenovirus-mediated gene therapy of CTLA4Ig or CD40Ig has a therapeutic potential for preventing rejection in composite tissue transplantation. Furthermore, a combination therapy of AxCTLA4Ig and AxCD40Ig was even more effective in preventing acute rejection and prolonging the survival of allografted limbs without apparent complication.
32
A Cell Culture Model for T Lymphocyte Clonal Anergy
Ronald H. Schwartz · Science · 1990 · 1.9K citations
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
Christian P. Larsen, Eric T. Elwood, Diane Z. Alexander et al. · Nature · 1996 · 1.5K citations
Long-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4lg
Deborah J. Lenschow, Yijun Zeng, J. Richard Thistlethwaite et al. · Science · 1992 · 1.1K citations